Hemostemix Inc. (CVE:HEM – Get Rating) shares passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of C$0.21 and traded as low as C$0.16. Hemostemix shares last traded at C$0.18, with a volume of 98,500 shares traded.
Hemostemix Stock Performance
The stock has a market cap of C$13.25 million, a price-to-earnings ratio of -1.75 and a beta of 0.61. The business has a fifty day simple moving average of C$0.21 and a 200 day simple moving average of C$0.18.
Hemostemix Inc, a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of critical limb ischemia in Canada and the United States, as well as for the treatment of heart and peripheral arterial diseases.
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.